Susan Desmond Hellmann, MD, MPH
Former Chief Executive Officer, Bill & Melinda Gates Foundation
Recorded, July 8, 2020

Join Dr. Sue Desmond-Hellmann, live Wednesday, July 8, 2020, as she shares her perspective on ways to think about, deal with, and potentially treat the COVID-19 pandemic.
Dr. Sue Desmond-Hellmann’s healthcare career has spanned major leadership roles in clinical, academic, industry, and philanthropic organizations. Most recently CEO of the Bill & Melinda Gate Foundation, Dr. Desmond-Hellmann has also served as Chancellor of UCSF and as President of Product Development at Genentech. She currently serves on the board of Pfizer. Dr. Desmond-Hellman received her MD from University of Nevada, Reno, and a Masters of Public Health from University of California, Berkeley. She completed her clinical training at UCSF.
An oncologist, Dr. Desmond-Hellmann spent time at the Uganda Cancer Institute studying HIV/AIDS and cancer. She is a champion of precision medicine and was involved in an effort to develop therapeutics for pandemics at the Gates Foundation.
.
“ Public understanding––and even more importantly, public trust––are the essential elements of fighting a pandemic.
––Dr. Sue Desmond-Hellman
Get ready to join Dr. Sue Desmond-Hellmann in conversation, Wednesday, July 8th.
In the meantime, we invite you to take a moment now to help shape this upcoming conversation.
Check out the list of questions submitted by other registered attendees, and then vote to support any that match your interests.
Feel free to add your own question. Then spread the word to make sure others have the chance to help move your question to the top of the shared list.
-
In your professional opinion what do you think is the limiting factor for SARS-CoV-2 testing? Why haven’t we done more contact tracing?
-
If there is a such a thing as herd immunity, isn’t a potential upside of this rush of positive case the possibility that we reach such a status sooner? Recognizing that overloading hospitals is not good and high risk people need to be addressed, but otherwise what is the risk of basically having the virus rush thru the population vs getting to the same outcome much more slowly?
votes